Key Highlights
- Fusion Antibodies attracted renewed investor interest after receiving acceptance for an Australian Patent application covering antibody-library design.
- International patent progress strengthens the commercial protection surrounding the proprietary OptiMAL platform.
- Revenue and underlying gross margins improved as market conditions began a gradual recovery.
- New and expanded projects with global pharmaceutical and biotechnology customers support a stronger commercial pipeline.
- The grant-funded Death Receptor Five programme has generated encouraging preclinical findings and potential licensing optionality.
- The outlook is cautiously constructive, although project timing, customer funding and cash requirements remain material risks.
Why Did Fusion Antibodies Plc (LSE:FAB) Rise by 7.14% on 25 August, 2026?
Fusion Antibodies shares rose by 7.14% as investors reassessed the value of its intellectual property and improving commercial pipeline. The recent acceptance of an Australian patent application supports the company’s strategy of building international protection around its antibody-library technology.
The application covers antibody families and methods used to design libraries for discovery, affinity maturation and sequence optimisation. Although acceptance is not the same as final patent grant, it indicates that the relevant claims have been considered patentable, subject to the remaining administrative process.
This development follows progress in other important jurisdictions, including patent milestones in North America and Asia. A broader patent estate increases the potential value of OptiMAL by making it more difficult for competitors to replicate its underlying design approach.
Investor sentiment is also supported by stronger trading. Fusion reported higher revenue, improved gross margins and a stronger cash position. Follow-on work from existing customers and new projects with larger pharmaceutical companies provide evidence that the Business is gradually moving beyond the weaker biotechnology-funding environment.
The share-price movement may additionally reflect speculative interest in the Death Receptor Five programme, where promising laboratory findings could eventually support a partnering or licensing transaction.
The business model of Fusion Antibodies Plc
Fusion operates a fee-for-service contract research model. Pharmaceutical, biotechnology and diagnostic companies engage Fusion to perform specialised antibody work that would otherwise require internal scientific teams, laboratory infrastructure and platform investment.
Services include antigen expression, antibody generation, sequencing, production, purification, characterisation, humanisation, affinity maturation, developability assessment and stable cell-line development. Revenue is generally recognised as customer projects progress through agreed stages.
The company’s proprietary CDRx platform is used to humanise antibodies so they are more suitable for therapeutic development. OptiMAL expands Fusion’s capabilities into antibody discovery through a mammalian library intended to identify candidates with stronger biological and developability characteristics.
Fusion can also generate value by transferring or licensing intellectual property created through internal and collaborative programmes. The antibody transfer agreement with Finn Therapeutics illustrates the potential to monetise a proprietary asset while maintaining an ongoing development relationship.
Grant-funded research reduces the amount of Shareholder Capital required to advance early scientific programmes. Successful programmes may create licensing assets, technical case studies and new commercial services.
Major Reasons Behind Upside
International patent expansion is a central positive factor. Intellectual-property protection is important because platform value depends on scientific differentiation and freedom to commercialise the technology across major pharmaceutical markets.
OptiMAL has received encouraging validation through work involving the US National Cancer Institute. Continued evidence that the library can generate relevant antibody candidates would improve its credibility with pharmaceutical customers and potential strategic partners.
Commercial momentum is also strengthening. Fusion has secured projects with global pharmaceutical organisations in the US and Europe. Larger customers can provide better funding stability and the potential for repeat work across multiple development programmes.
An existing US biotechnology customer expanded its stable cell-line development programme, demonstrating customer satisfaction and Fusion’s ability to convert initial projects into follow-on revenue. Such repeat business can improve visibility within an otherwise variable project-based model.
The Death Receptor Five collaboration with Queen’s University Belfast offers additional optionality. The candidate has demonstrated targeted activity in colorectal cancer cells, while mechanistic work suggests that its antibody design may address limitations that affected earlier industry programmes. Further animal testing is required before the commercial potential can be assessed.
Microfluidic technology is helping Fusion shorten cell-line development timelines. Faster delivery can make the company more competitive because biotechnology customers place significant value on reducing the time required to reach clinical development.
The US-Iran war has limited direct relevance to Fusion’s science. However, higher energy costs, disrupted logistics and weaker Capital Markets could affect laboratory expenses and customer funding. Healthcare innovation may retain defensive appeal, but smaller biotechnology companies remain sensitive to risk appetite.
What Are the Major Risks Investors Should Consider?
Execution risk is significant because Fusion must translate patent and platform progress into commercial contracts. Scientific validation does not guarantee meaningful revenue.
Project-based income can be volatile. Customer studies may be delayed, reduced or cancelled, particularly when early-stage biotechnology companies face funding pressure. Engagement with larger pharmaceutical groups may reduce this risk but cannot eliminate it.
Funding risk remains important because the company is small and continues investing in research, commercial development and laboratory capabilities. Grant support is helpful, but future capital raising could dilute shareholders if cash generation remains insufficient.
Regulatory risk includes laboratory standards, intellectual-property disputes, data integrity and future requirements affecting therapeutic-development services. The company’s customers also face complex drug-approval processes that can influence project continuity.
Competitive pressure comes from larger contract research organisations, specialist antibody companies and internal pharmaceutical teams. Competitors may possess greater scale, broader service offerings or larger commercial networks.
Operational risks include staff retention, laboratory capacity, equipment performance and the reproducibility of scientific results. Economic uncertainty and geopolitical exposure may affect client budgets, currencies, Supply chains and the availability of specialist materials.
What Is the Dividend Outlook?
Fusion Antibodies is unlikely to pay a dividend while it remains focused on commercial recovery and platform development. Capital-allocation priorities include strengthening OptiMAL, supporting grant-funded programmes, expanding customer relationships and maintaining adequate working capital.
The Investment case is based on potential capital appreciation rather than income. Shareholder value would most likely arise from stronger service revenue, improved margins, platform licensing, intellectual-property monetisation or strategic partnerships.
A dividend would become relevant only after Fusion establishes consistent profitability and sustainable positive cash generation.
How Does Fusion Antibodies Plc Compare With Other Industry Peers?
Fusion differentiates itself through deep expertise in antibody humanisation and engineering, combined with an expanding discovery capability. Its integrated service range allows clients to move from early antibody generation toward optimisation and production using one specialist provider.
Compared with larger contract research peers, Fusion has fewer resources, lower revenue Diversification and less financial flexibility. However, its smaller structure may support scientific responsiveness and closer collaboration with customers.
The OptiMAL library provides a proprietary element that distinguishes Fusion from purely service-based competitors. International patent protection and external validation could increase its strategic value if customer adoption develops successfully.
Fusion’s growth profile is potentially attractive because antibody therapeutics remain important across oncology, immunology and other disease areas. Its risk profile is elevated due to small scale, project variability and dependence on successful commercialisation.
What Are the Bull and Bear Cases for LSE:FAB?
Bull Case:
- OptiMAL patents progress across additional major territories.
- External validation converts into commercial platform contracts.
- Global pharmaceutical customers generate repeat and expanded work.
- Improving project mix supports further Margin expansion.
- The Death Receptor Five programme produces encouraging animal data.
- A licensing or strategic Partnership monetises proprietary antibody assets.
Bear Case:
- Patent progress fails to generate meaningful commercial demand.
- Biotechnology funding weakness delays customer projects.
- Revenue remains volatile due to contract timing.
- Cash requirements lead to additional shareholder dilution.
- Larger competitors win projects through greater scale and resources.
- Proprietary research programmes Fail during further testing.
Technical Levels to Watch
- Support Zone: The recent consolidation range may provide initial support during any pullback.
- Resistance Levels: Previous recovery highs could create selling pressure and test the strength of demand.
- Volume Trends: Sustained higher Volume would provide stronger confirmation of genuine accumulation.
- Momentum Indicators: Momentum has turned positive, although the shares remain vulnerable to sharp movements because of limited liquidity.
What Does the ESG Investment Case Look Like?
Fusion’s social contribution lies in helping pharmaceutical and diagnostic companies develop potentially valuable healthcare products more efficiently. Faster antibody discovery and optimisation could shorten development timelines for important treatments.
Its environmental footprint is lower than that of heavy industry, but laboratory energy use, biological waste, chemicals and cold-chain requirements need responsible management.
Governance priorities include scientific integrity, transparent reporting, ethical research and protection of customer data and intellectual property. Work involving therapeutic antibodies must follow appropriate laboratory and animal-welfare standards.
ESG-related opportunities include reducing unnecessary development work through better early candidate selection and using efficient technologies to shorten laboratory processes. Risks include overstating preclinical findings or failing to maintain rigorous quality controls.
Outlook
Fusion Antibodies enters its next phase with improving margins, a stronger commercial pipeline and expanding international protection for OptiMAL. Engagement with larger pharmaceutical customers provides encouraging validation of the company’s strategy.
Patent milestones in Australia and other territories improve the platform’s long-term commercial position, while the Death Receptor Five programme creates potential licensing optionality. Grant funding also allows Fusion to advance research while limiting some of the burden on its balance sheet.
The outlook is cautiously constructive. Sustained upside will require repeat customer orders, stronger cash generation and evidence that proprietary technologies can produce meaningful commercial returns. Until then, the shares remain a higher-risk biotechnology opportunity sensitive to contract timing and financing conditions.






Please wait processing your request...